In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Inter Parfums Premiere H&BA Line Intimate Expected To Fuel Mass Sales

This article was originally published in The Rose Sheet

  • News
  • The Rose Sheet

Executive Summary

Inter Parfums' Intimate H&BA line is expected to boost sales in the company's mass market division after it is rolled out this month, CEO Jean Madar said.

You may also be interested in...



Inter Parfums Seeking To Acquire Tristar Fragrance Portfolio For $10 Mil.

Inter Parfums has signed a letter of intent with fragrance marketer Tristar to acquire portions of the company's mass market fragrance portfolio

Inter Parfums Seeking To Acquire Tristar Fragrance Portfolio For $10 Mil.

Inter Parfums has signed a letter of intent with fragrance marketer Tristar to acquire portions of the company's mass market fragrance portfolio

Inter Parfums Celine Fragrance Launch To Bolster 2001 Sales

Inter Parfums' premiere Celine fragrances for men and women are expected to help the firm boost year-end sales 13% to $113 mil., CEO Jean Madar announced during the company's second quarter conference call Aug. 8.

Table

View full table

Related Content

HBW Insight
HBW Insight
Tags:
Latest Headlines

As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure

South Korea Sees Pharma Leadership Transition

FDA-EMA Advice Pilot For Complex Generics: What Does Industry Have To Say?

The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’

See All
UsernamePublicRestriction

Register

RS009247

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By